Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Research Abstract |
A basic research was performed to develop a novel method in preventing sun-induced skin cancers and melanomas, and progressive neurological disease in xeroderma pigmentosum (XP) patients using agents that can stimulate DNA repair capacity through the elevation of cellular cAMP level and CREB activity. Our results suggested that DBcAMP can stimulate DNA repair capacity in neuroblastoma cells. Cyclopurines are candidates to be involved with XP neurological disease. Thus, we established a novel monoclonal antibody specific for a type of cyclopurine, cyclo-dA, in order to determine whether DBcAMP can also stimulate repair capacity for cyclopurines.
|